linjc16/ctgov huggingface dataset:
A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
A study to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases

Detailed Description
-----------------
A multi-centre real-world non-interventional observational study to retrospectively collect the study data on patient demographic/tumor biological characteristics and clinical treatments to compare patient survivals in the N2 patients with non-small cell lung cancer in the subgroups of lymph skip metastases and non-skip metastases.

Official Title
-----------------
A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with surgeries from 2014 to 2017; Pathologically diagnosed patients with non-small cell lung cancer; Age > 18 years old; Patients with chest surgeries before hospitalization; Patients with N2 lymph nodes (+) after surgeries who received lymphadenectomy (Group 10 and 11 lymph nodes); Exclusion Criteria: - Patients with radiotherapies, chemotherapies and biological therapies for tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| N2 non-small cell lung cancer<br>Chinese patients with N2 non-small cell lung cancer | Procedure: Surgery<br>* Surgeries plus dissection of lymph nodes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in overall survival (OS) | OS difference in the subgroups of N2 patients with lymph skip metastases and non-skip metastases | 2014 - 2017 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of N2 patients with lymph skip metastases | Percentage of N2 patients with lymph skip metastases | 2014 - 2017 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chinese, real-world evidences, NSCLC, lymph skip metastases
Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective study, screening patients with systemic PET / CT scan in our department, enrolling the ones who meet the criteria, collect their information and resting state brain PET images.Then make the brain metabolic network analysis and statistical analysis to explore the PET brain metabolic network of non-small cell lung cancer patients and the effect of chemotherapy drugs on brain metabolic network in patients with advanced lung cancer.

Detailed Description
-----------------
Enroll Participants Collect PET/CT Images Images Analysis Statistical Analysis

Official Title
-----------------
The Fifth Affiliated Hospital of Sun Yat-sen University

Conditions
-----------------
Advanced Non-small-cell Lung Cancer

Intervention / Treatment
-----------------
* Other: None of any intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with advanced non-small cell lung cancer without any treatment and pathological confirmed non-small cell lung cancer. Exclusion Criteria: Brain tumors (primary or metastasis), previous surgery, radiotherapy, chemotherapy, stroke, head trauma, psychiatric history (insomnia, depression, mania, schizophrenia and other psychiatric disorders), or history of drug dependence (e. g. sedatives, sleeping pills or sedatives)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with untreated non-small cell lung cancer<br> | Other: None of any intervention<br>* The patients did not have any intervention.<br>|
| Patients with non-small cell lung cancer after chemotherapy<br> | |
| Normal controls<br> | Other: None of any intervention<br>* The patients did not have any intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death |  | 1-5 years |
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission

Study Overview
=================
Brief Summary
-----------------
HIV infected individuals with vitamin A deficiency may be more likely to transmit the virus to others than HIV infected individuals who have normal levels of vitamin A. The presence of HIV DNA in vaginal secretions may indicate a greater risk for transmission of HIV to others. The purpose of this study is to determine if taking vitamin A decreases the level of HIV DNA in vaginal secretions.

Detailed Description
-----------------
Vitamin A deficiency leads to pathological changes in mucosal epithelium, including the vagina, and is correlated with immune dysfunction in both HIV-1 infected and uninfected individuals. Recent studies of genital tract shedding of HIV-1 DNA in infected women have found that lower serum concentrations of vitamin A were strongly associated with detection of HIV-1 in vaginal secretions. In addition, maternal vitamin A deficiency has been associated with significantly increased risk of vertical HIV-1 transmission. This study will assess the effect of vitamin A supplementation on the prevalence and quantity of HIV-1 DNA and RNA in cervical and vaginal secretions. Participants in this study will be HIV infected nonpregnant women in Mombasa, Kenya. Participants will be randomized to receive 6 weeks of daily dosage of either 10,000 IU vitamin A or placebo. Cervical and vaginal swabs will be obtained at enrollment and at Week 6 for detection and quantification of HIV-1 DNA and RNA. In addition, venous blood will be obtained at the two time points for quantification of plasma HIV-1 RNA, CD4 lymphocyte count, and serum vitamin A levels.

Official Title
-----------------
Prevention of HIV Shedding in Women - Trial of Vitamin A

Conditions
-----------------
HIV Infections, Vitamin A Deficiency, HIV Seronegativity

Intervention / Treatment
-----------------
* Drug: Vitamin A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV infected Exlusion Criteria: Pregnant
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vitamin A|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV-1, Women, Vitamin A, Shedding
Hormone Replacement Therapy and Insulin Action: A Double-Blind, Parallel, Placebo-Controlled Hormone Intervention Study in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
Considerable controversy exists regarding the effect of estrogen and progesterone on insulin sensitivity in postmenopausal women. Thus, the goal is to examine the effect of estradiol and progestin on in vivo insulin sensitivity and pathways of intracellular glucose metabolism in postmenopausal women. This will be accomplished by examining the effects of unopposed estrogen (CEE) or combination estrogen and progestin (CEE/MPA) versus placebo therapy in 30 early menopausal women (defined from 6 months to 3 years post-cessation of menses). Women will be treated for 16 weeks and the outcome measures will be: 1) insulin sensitivity and glucose oxidation as determined by euglycemic clamp, 2) assessments of insulin sensitivity on muscle biopsy cultures with the primary endpoints being glucose uptake and glycogen accumulation/synthesis, 3) protein levels of insulin action cascade steps based on muscle biopsy Western blots.

Conditions
-----------------
Menopause

Intervention / Treatment
-----------------
* Drug: Hormone Replacement Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 months to 3 years since cessation of menses BMD 24-33 no surgically induced menopause

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Hormone Replacement Therapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Retrospective Clinical and Functional Evaluation of Patients Undergoing Knee Replacement With Small Implants

Study Overview
=================
Brief Summary
-----------------
Retrospective evaluation of: Functional results Clinical results Survivorship of knee replacement performed with small implants, isolated or combined

Detailed Description
-----------------
Retrospective evaluation of partial knee replacements (medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI) performed in the Joint Replacement Department of the IRCCS Istituto Ortopedico Galeazzi. evaluation includes: clinical examination, functional results, survivorship at 1, 2, 5 , 10 and 15 years.

Official Title
-----------------
Retrospective Clinical and Functional Evaluation of Patients Undergoing Knee Replacement With Small Implants

Conditions
-----------------
KNEE REPLACEMENT

Intervention / Treatment
-----------------
* Procedure: PARTIAL KNEE REPLACEMENT


Participation Criteria
=================
Eligibility Criteria
-----------------
inclusion criteria: patients receiving medial UNI or lateral UNI or patellofemoral replacement or combined UNI+ patellofemoral replacement or combined medial and lateral UNI age > 18 years exclusion criteria patients receiving total knee replacement patients having revision or a knee replacement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: partial knee replacement<br>medial UNI, lateral UNI, patellofemoral replacement, combined UNI+ patellofemoral replacement, combined medial and lateral UNI | Procedure: PARTIAL KNEE REPLACEMENT<br>* PARTIAL KNEE REPLACEMENT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KNEE SOCIETY SCORE | total scale range: 0 (minimum)-100 (maximum); excellent results: 80-100 | 2 years | 
| KNEE SOCIETY SCORE | total scale range: 0 (minimum)-100 (maximum); excellent results: 80-100 | 5 years | 
| KNEE SOCIETY SCORE | total scale range: 0 (minimum)-100 (maximum); excellent results: 80-100 | 10 years |
Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.

Official Title
-----------------
Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication

Conditions
-----------------
Head and Neck Cancers Patients

Intervention / Treatment
-----------------
* Diagnostic Test: Serum levels of immunologic profiles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department. Exclusion Criteria: Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease progression | Tumor local recurrence or distant metastasis | Three years |
A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days

Official Title
-----------------
Open Study to Access the Efficacy and Safety of Meloxicam 7.5mg in Patients With Osteoarthritis of the Knee

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Meloxicam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Osteoarthritis of the knee requiring the therapy with non-steroidal anti-inflammatory drugs (NSAIDs) Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 34 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Meloxicam<br> | Drug: Meloxicam<br> <br> * Other names: Mobic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in pain on active movement assessed by a 100 mm visual analogue scale (100 mm, VAS) |  | Baseline, 8 weeks after first drug administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Lequesne index |  | Baseline, 8 weeks after first drug administration | 
| Change from baseline in physical examination (tenderness) |  | Baseline, 8 weeks after first drug administration | 
| Assessment of significant change from baseline in status according endoscopy |  | Baseline, 8 weeks after first drug administration | 
| Assessment of significant change from baseline in gastrointestinal (GI) symptoms score |  | Baseline, 8 weeks after first drug administration | 
| Assessment of significant change from baseline in laboratory values |  | Baseline, 8 weeks after first drug administration | 
| Number of Patients with Adverse Events |  | Up to 8 weeks after first drug administration | 
| Assessment of significant change from baseline in physical examination (swelling) |  | Baseline, 8 weeks after treatment |
Exercise Adherence in Home-based Cardiac Rehabilitation

Study Overview
=================
Brief Summary
-----------------
The study will investigate the influencing factors of exercise adherence of home-based cardiac rehabilitation in patients with coronary artery disease.

Detailed Description
-----------------
The study will conduct a quantitative questionnaire survey. Patients with coronary artery disease in home-based cardiac rehabilitation will receive investigation of the influencing factors of exercise adherence.

Official Title
-----------------
Influencing Factors of Exercise Adherence in Home-based Cardiac Rehabilitation in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of coronary artery disease; Age ≤75 years old; Participated in home-based cardiac rehabilitation ≥12 weeks; Volunteer to participate in this study. Exclusion Criteria: Have other serious acute or chronic diseases; Have severe audio-visual or speech impairments that may affect understanding and answering questions.

Ages Eligible for Study
-----------------
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with coronary artery disease<br>patients with coronary artery disease | Other: survey<br>* questionnaire about the influencing factors of home-based cardiac rehabilitation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Influencing factors of exercise adherence | Influencing factors of exercise adherence in home-based cardiac rehabilitation | The influencing factors of exercise adherence in home-based cardiac rehabilitation will be measured by the Theory of Planned Behavior Questionnaire through study completion, an average of 1 year | 
| Exercise adherence | Adherence of home-based exercise training | The exercise adherence will be measured by the Home-based Exercise Training Adherence Questionnaire through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease, Home-based cardiac rehabilitation, Exercise adherence
Investigation of Dental Plaque and Gingival Index

Study Overview
=================
Brief Summary
-----------------
Investigation of inhibitory effect of prototype toothpaste on dental plaque formation via modified gingival margin plaque index method.

Official Title
-----------------
Investigation of Dental Plaque and Gingival Index

Conditions
-----------------
Dental Plaque

Intervention / Treatment
-----------------
* Drug: Sodium Monofluorophosphate
* Drug: Triclosan/Fluoride/Copolymer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Be aged 18 to 65 years inclusive Have a minimum of 20 natural uncrowned teeth (excluding 3rd molars) present Give written informed consent Be in good general health Must discontinue oral hygiene for 24-hrs.after initial appointment. No known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the dental/medical professional monitoring the study Exclusion Criteria: Medical condition which requires pre-medication prior to dental visits/procedures Advanced periodontal disease 5 or more decayed, untreated dental sites Diseases of the soft or hard oral tissues Orthodontic appliances Abnormal salivary function Use of drugs that can currently affect salivary flow Use of antibiotics one (1) month prior to or during this study Use of any over the counter medications other than analgesics (i.e. aspirin, ibuprofen, acetaminophen, naproxyn) Pregnant or breastfeeding. Participation in another clinical study in the month preceding this study Allergic to common dentifrice ingredients. Immune compromised individuals (HIV, AIDS, immuno suppressive drug therapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A - Marketed fluoride toothpaste<br> | Drug: Sodium Monofluorophosphate<br>* Brush teeth and evaluate plaque score after one use of the study toothpaste<br>* Other names: Colgate Great Regular Flavor toothpaste;|
| Active Comparator: B -Triclosan/NaF/CoPolymer toothpaste<br> | Drug: Triclosan/Fluoride/Copolymer<br>* Brush teeth and evaluate plaque score after one use of the study toothpaste<br>* Other names: Colgate Total toothpaste;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gingival Margin Plaque Index | Scale 0 to 100% of tooth gingival margin covered by plaque. (0=no plaque, 100%=100% of the tooth's gingival margin is covered in plaque). The lower the score less dental plaque is present along the gum line and therefore the better the performance of the study treatment. | 1 day |
The Type of Hepatoglobin in IUGR

Study Overview
=================
Brief Summary
-----------------
Intra Uterine Growth Restriction is associated with increased oxidative stress. Haptoglobin (Hp) is an abundant plasma glycoprotein produced in the liver. The function of Hp is as anti oxidant agent, it binds free hemoglobin (Hb) released from red blood cells to decrease oxidative tissue damage. There are 3 differenet genotype of haptoglobin Hp 1-1 Hp 1-2 and Hp 2-2 with different anti oxidant properties and different prevalence ( Hp 1-1, Hp 1-2 and Hp 2-2approximately 16%, 48% and 36% respectively) . we hypotheise that IUGR will be more common and severe in the Hp 2-2 genotype with the less anti oxidant properties.

Official Title
-----------------
The Type of Hepatoglobin in IUGR

Conditions
-----------------
Haptoglobin Type

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnancies complicated with IUGR - Exclusion Criteria: NOT INTERESTED DO PARTICIPATE -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IUGR<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| type of haptoglobin | severity of iugr | 10 weeks |